|
Psychedelic therapy using psilocybin derived from medicinal mushrooms has received breakthrough therapy designation from the FDA. COMPASS Pathways, the company that received that designation, just had a historic $100 million IPO on the NASDAQ and the stock rocketed from $14 to $45 and is still sitting at $36.
It’s created a buying frenzy in the sector and we’re bullish on one psychedelic stock that has been making all the right moves lately.
It’s one of the hottest stocks in Canada and it’s one of the few companies fully licensed by Health Canada to cultivate, transfer, sell, and export pharmaceutical-grade psilocybin.
It’s the new era of medicine.
Get the name and symbol here right now.
|